3 insiders hold 48MM shares in advance of efficacy data I'm anticipating decent news Wednesday.
As per NR last Tuesday March 26:
Early data of BriaCell's combination study of lead candidate,
Bria-IMT(TM), with KEYTRUDA(R) (by Merck & Co., Inc.) in advanced breast
cancer will be announced at the American Association for Cancer Research
(AACR) Annual Meeting in Atlanta, Georgia, on April 3, 2019.
Just 3 insiders are now holding almost 48 million shares out of 164.55 million outstanding. It's getting hard to pick up shares cheap, despite the fact that something like 15 million shares traded at $0.10 and below around the end of 2018.
If Bria-IMT + KEYTRUDA efficacy data is OK we can look forward to a very positive scenario for the health and wealth of the stakeholders here.
Bria-IMT has already yielded outstanding safety and efficacy results on it's own.
Bria-IMT + KEYTRUDA have (Dec 2018) had outstanding safety results together.
KEYTRUDA is already FDA approved to treat other cancer types (such as advanced lung cancer).
It looks good from the perspective of an outsdier.
Apparently it also looks good to insiders.
-GLTA